Novavax Inc (NVAX)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$7.10

Buy

$7.15

arrow-down$-0.46 (-6.23%)

Prices updated at 28 May 2025, 09:49 EDT

Prices minimum 15 mins delay

Prices in USD

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

NASDAQ

-0.51%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Ms. Margaret G. McGlynn

CEO

Mr. John C. Jacobs

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,992

Head office

700 Quince Orchard Road

Gaithersburg

United States

20878

+1 240 268-2000

ir@novavax.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Margaret G. McGlynn Chairman of the Board	0.08m
Mr. John J. Trizzino Co-President and Chief Operating Officer	0.58m
Mr. Charles W. Newton Independent Director	-
Dr. John W. Shiver, PhD Independent Director	-
Dr. Gregg H. Alton, J.D. Independent Director	0.07m
Mr. Richard J. Rodgers Independent Director	0.09m
Mr. David M. Mott Independent Director	0.08m
Mr. Mark J. Casey Executive Vice President, Chief Legal Officer and Corporate Secretary	0.56m
Dr. Richard H. Douglas, PhD Independent Director	0.08m
Ms. Rachel K. King Independent Director	0.07m
Mr. John C. Jacobs Director, President and Chief Executive Officer	0.75m
Mr. James P. Kelly Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer	0.55m
Ms. Elaine O'Hara Executive Vice President and Chief Strategy Officer	0.54m
Dr. Ruxandra Draghia-Akli Executive Vice President and Head of Research and Development	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	15,674,378
Vanguard Group Inc. ( Junked)	15,430,034
BlackRock Inc	12,967,029
Shah Capital Management	11,131,846
State Street Corp	7,039,158

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
24 Dec 2024	-
13 Dec 2024	-
11 Dec 2024	-
11 Dec 2024	-
11 Dec 2024	-
11 Nov 2024	-
11 Nov 2024	-
29 Oct 2024	-
29 Oct 2024	-
19 Aug 2024	-
19 Aug 2024	-
19 Aug 2024	-
21 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
17 Jun 2024	-
17 Jun 2024	-
17 Jun 2024	-
17 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.